(Q37866759)

24 August 2017

1 reference

title

Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp (English)

1 reference

24 August 2017

Paul L McCormack

1

1 reference

24 August 2017

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

709-730

1 reference

Pathogenesis and clinical features of psoriasis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Psoriasis: advances in pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Topical treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Calcipotriene/betamethasone in the treatment of psoriasis: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Calcipotriol/betamethasone dipropionate for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Bioavailability of betamethasone dipropionate when combined with calcipotriol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Microcirculatory modifications of psoriatic lesions during topical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Psoriasis: consensus on topical therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

Objective assessment of compliance with psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207300-000000000-00000

The DESIRE study--psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice

21 January 2018

1 reference

12 December 2020

Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris

1 reference

12 December 2020

Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product

1 reference

12 December 2020

Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betameth

1 reference

12 December 2020

Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation

1 reference

12 December 2020

Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany

1 reference

12 December 2020

Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris

1 reference

12 December 2020

The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?

1 reference

12 December 2020

Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis

1 reference

12 December 2020

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

1 reference

12 December 2020

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris

1 reference

12 December 2020

Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study

1 reference

12 December 2020

10.2165/11207300-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference